Skip to main navigation menu Skip to main content Skip to site footer

SARS-CoV-2 in older adult with neurodegenerative disease

SARS-CoV-2 en el adulto mayor con enfermedad neurodegenerativa




Section
Artículo Corto

How to Cite
González Devia, J. L., Torres Pérez, M. L., & Cuartas Méndez, D. M. (2020). SARS-CoV-2 in older adult with neurodegenerative disease. NOVA, 18(35), 121-127. https://doi.org/10.22490/24629448.4196

Dimensions
PlumX
license

Licencia Creative Commons

NOVA by http://www.unicolmayor.edu.co/publicaciones/index.php/nova is distributed under a license creative commons non comertial-atribution-withoutderive 4.0 international.

Furthermore, the authors keep their property intellectual rights over the articles.

 

Johanna Lizeth González Devia

    Myriam Leonor Torres Pérez

      Diana María Cuartas Méndez


        Despite the many neurological complications associated with SARS-CoV-2 infection, it isn´t still clear whether these symptoms are the result of direct neural injury or due to some other reason. Currently, it appears that most of the neurological symptoms of COVID-19 are nonspecific and secondary to systemic disease.

        To date, there is not enough scientific evidence to confirm that SARS-CoV-2 virus directly affects the central or peripheral nervous system in humans. This short article presents the implications of SARS-CoV-2 in the elderly with neurodegenerative disease, as well as the related mechanisms of action in the nervous system.


        Article visits 319 | PDF visits 249


        Downloads

        Download data is not yet available.

        1. OMS. Brote de enfermedad por coronavirus (COVID-19) 2020 [cited 2020 15 de julio]. Available from: https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019.

        2. Das G, Mukherjee N, Ghosh S. Neurological Insights of COVID-19 Pandemic. ACS Chem Neurosci. 2020;11(9):1206-9.

        3. Serrano-Castro PJ, Estivill-Torrús G, Cabezudo-García P, Reyes-Bueno JA, Ciano Petersen N, Aguilar-Castillo MJ, et al. Influencia de la infección SARS-CoV-2 sobre enfermedades neurodegenerativas y neuropsiquiátricas: ¿una pandemia demorada? Neurología. 2020;35(4):245-51.

        4. Asad AS, Zuccato CF, Candia AJN, Gottardo MF, Ayala MAM, Theas MS, et al. Papel del péptido mitocondrial humanina como blanco terapéutico en cáncer y neurodegeneración. Nova. 2019;17(32):9-24.

        5. Niazkar HR, Zibaee B, Nasimi A, Bahri N. The neurological manifestations of COVID-19: a review article. Neurol Sci. 2020:1-5.

        6. Abboud H, Abboud FZ, Kharbouch H, Arkha Y, El Abbadi N, El Ouahabi A. COVID-19 and SARS-Cov-2 Infection: Pathophysiology and Clinical Effects on the Nervous System. World Neurosurg. 2020;140:49-53.

        7. Hascup ER, Hascup KN. Does SARS-CoV-2 infection cause chronic neurological complications? Geroscience. 2020:1-5.

        8. Boika AV. A Post-COVID-19 Parkinsonism in the Future? Mov Disord. 2020:10.1002/mds.28117.

        9. Monteiro-Junior RS. COVID-19: Thinking about further mental and neurological disorders. Med Hypotheses. 2020;143:109894-.

        10. Salari M, Zali A, Ashrafi F, Etemadifar M, Sharma S, Hajizadeh N, et al. Incidence of Anxiety in Parkinson's Disease During the Coronavirus Disease (COVID-19) Pandemic. Mov Disord. 2020:10.1002/mds.28116.

        11. Singh AK, Bhushan B, Maurya A, Mishra G, Singh SK, Awasthi R. Novel coronavirus disease 2019 (COVID-19) and neurodegenerative disorders. Dermatol Ther. 2020:e13591-e.

        12. Garg D, Dhamija RK. The Challenge of Managing Parkinson's Disease Patients during the COVID-19 Pandemic. Ann Indian Acad Neurol. 2020;23(Suppl 1):S24-S7.

        13. Cheng Q, Yang Y, Gao J. Infectivity of human coronavirus in the brain. EBioMedicine. 2020;56:102799-.

        14. Pereira A. Long-Term Neurological Threats of COVID-19: A Call to Update the Thinking About the Outcomes of the Coronavirus Pandemic. Front Neurol. 2020;11:308-.

        15. Lippi A, Domingues R, Setz C, Outeiro TF, Krisko A. SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration. Mov Disord. 2020;35(5):716-20.

        Sistema OJS 3.4.0.5 - Metabiblioteca |